Small Clinical Benefit Seen for Race-Aware Over Unaware Risk Predictions
TUESDAY, Dec. 3, 2024 -- The clinical benefit of race-aware over race-unaware disease risk predictions is smaller than expected, according to a study published online Dec. 3 in the Annals of Internal Medicine.
Madison Coots, from Harvard University in Cambridge, Massachusetts, and colleagues present a decision analytic framework for considering the potential benefits of race-aware over race-unaware risk predictions. A cross-sectional study involving U.S. adults was conducted using cardiovascular disease, breast cancer, and lung cancer as case studies. Race-unaware predictions were generated via statistical marginalization, starting with risk predictions from clinically recommended race-aware models. The utility gains of the race-aware over the race-unaware models were estimated based on a simple utility function assuming constant costs of screening and constant benefit of disease detection.
The researchers found that compared with the race-aware predictions as the benchmark, the race-unaware predictions were substantially miscalibrated across racial and ethnic groups. At the population level, the clinical net benefit of race-aware over race-unaware predictions was smaller than anticipated. This result stemmed from two patterns: (1) 95 percent or more of individuals would receive the same decision across all three diseases, irrespective of whether race and ethnicity are included in the risk model; and (2) the net benefit of screening or treatment was relatively small for those who received different decisions because these patients have disease risks close to the decision threshold. Race-aware models may have a more substantial net benefit when used to inform rationing.
"Our results suggest that race-aware risk models yield smaller gains in net benefit over race-unaware models than the improvement in predictions might suggest," the authors write.
Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.
Read this next
Cancer Survival Lower in Rural Areas
WEDNESDAY, Oct. 1, 2025 -- Five-year cancer survival rates for each stage of cancer (localized, regional, and distant) is lower in nonmetropolitan areas for Black and White...
Loss of Smell May Linger After COVID-19
WEDNESDAY, Oct. 1, 2025 -- Self-reported change or loss in smell or taste is an accurate signal of verified hyposmia after COVID-19, although there is also a high rate of hyposmia...
Elderly Patients Benefit From Screening Mammography
WEDNESDAY, Oct. 1, 2025 -- Patients with breast cancer diagnosed at 80 years of age or older who received screening mammography present with earlier-stage disease and have better...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.